[go: up one dir, main page]

MX2022016590A - Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. - Google Patents

Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.

Info

Publication number
MX2022016590A
MX2022016590A MX2022016590A MX2022016590A MX2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A MX 2022016590 A MX2022016590 A MX 2022016590A
Authority
MX
Mexico
Prior art keywords
dosing regimen
inflammatory bowel
bowel disease
treating inflammatory
induction
Prior art date
Application number
MX2022016590A
Other languages
English (en)
Inventor
Mina Hassan-Zahraee
Gang Li
Mary Lynn Baniecki
Kenneth Eugene Hung
Li Xi
Zhan Ye
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022016590A publication Critical patent/MX2022016590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un método para el tratamiento de la enfermedad inflamatoria intestinal (IBD) en un paciente, el método comprende administrar al paciente un anticuerpo anti-ligando 1A similar al TNF (TL1A) en un régimen de dosificación de inducción suficiente para mejorar los signos y síntomas de la IBD durante al menos 12 semanas después del inicio del tratamiento con el anticuerpo anti-TL1A, dicho régimen de dosificación de inducción comprende una pluralidad de dosis de inducción individuales, en el que el método además comprende administrar al paciente un régimen de dosificación de mantenimiento posterior después de completar el régimen de dosificación de inducción, dicho régimen de dosificación de mantenimiento comprende una pluralidad de dosis de mantenimiento individuales separadas entre sí por al menos 2 semanas.
MX2022016590A 2020-06-26 2021-06-23 Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a. MX2022016590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044390P 2020-06-26 2020-06-26
PCT/IB2021/055546 WO2021260577A2 (en) 2020-06-26 2021-06-23 Methods of treating inflammatory bowel disease with tl1a antibodies

Publications (1)

Publication Number Publication Date
MX2022016590A true MX2022016590A (es) 2023-02-01

Family

ID=76730925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016590A MX2022016590A (es) 2020-06-26 2021-06-23 Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.

Country Status (9)

Country Link
US (1) US20230235070A1 (es)
EP (1) EP4171632A2 (es)
JP (1) JP2022022994A (es)
KR (1) KR20230025898A (es)
CN (1) CN116322762A (es)
BR (1) BR112022025667A2 (es)
CA (1) CA3187966A1 (es)
MX (1) MX2022016590A (es)
WO (1) WO2021260577A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CA3098374A1 (en) 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
US20200362025A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
TW202346344A (zh) * 2022-01-07 2023-12-01 美商普羅米修斯生物科學股份有限公司 以tl1a抑制劑及il23抑制劑的組合治療發炎疾病之方法
CN119894931A (zh) 2022-07-27 2025-04-25 赛福伦有限责任公司 用于治疗溃疡性结肠炎和克罗恩病的抗tl1a抗体
WO2024173877A1 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
CN118497088B (zh) * 2024-07-18 2024-10-01 北京大学人民医院 变异链球菌及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
MX2016002879A (es) * 2013-09-06 2016-08-17 Cedars Sinai Medical Center Sistemas, dispositivos y metodos para la terapia anti-tl1a.
CN105814081B (zh) * 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
CN117286238A (zh) * 2016-05-20 2023-12-26 西达-赛奈医疗中心 基于基因的炎性肠病诊断
US10322174B2 (en) * 2016-10-26 2019-06-18 Cedars-Sinai Medical Center Neutralizing anti-TL1A monoclonal antibodies
CA3098374A1 (en) * 2018-04-25 2019-10-31 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies

Also Published As

Publication number Publication date
CN116322762A (zh) 2023-06-23
US20230235070A1 (en) 2023-07-27
WO2021260577A2 (en) 2021-12-30
WO2021260577A3 (en) 2022-04-28
KR20230025898A (ko) 2023-02-23
JP2022022994A (ja) 2022-02-07
EP4171632A2 (en) 2023-05-03
CA3187966A1 (en) 2021-12-30
BR112022025667A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
MX2022016590A (es) Metodos de tratamiento de la enfermedad inflamatoria intestinal con anticuerpos tl1a.
RU2013120957A (ru) Способы лечения псориаза с использованием антагонистов il-17
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
EA201892190A1 (ru) Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы
RU2015104001A (ru) Комбинированная терапия для лечения глиобластомы
RU2013110844A (ru) АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ
ZA202210079B (en) Compositions and methods for treating or preventing inflammatory diseases including diabetes mellitus 10 type i and type ii and thyroid diseases
Marjani et al. Drug resistance pattern and outcome of treatment in recurrent episodes of tuberculosis.
RU2016108809A (ru) Способы повышения форсированного объема выдоха у больных астмой с применением бенрализумаба
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
AU2020319677A8 (en) Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
Lim et al. The Role of Intravenous Immunoglobulin (IVIG) in Reducing Infection Risk in Multiple Myeloma (MM) Patients Receiving Immune-Based Therapies: A Single Center Experience
Offidani et al. Factors associated with the probability to skip subsequent lines of therapy: analysis of 321 Multiple Myeloma (MM) patients in a single tertiary centre: SP-127
Fu et al. Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study
Sadeghi et al. Immunotherapy of Prostate Cancer may Change mRNA Level of Virulence Factor Genes in E. Faecalis of Microflora
Laplaud et al. Recommendations for the management of multiple sclerosis relapses
MX2022001154A (es) Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
YU et al. Clinical observation of Ruyi jinhuang powder combined with ICIs in the treatment of advanced liver cancer complicated with dampness and heat syndrome of liver and gallbladder
Sun et al. Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis. Diagnostics 2022, 12, 2954
Palladini et al. AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
Klein et al. Serum-derived Bovine Immunoglobulin Isolate: A New Medical Food for the Clinical Dietary Management of Enteropathy: 1881
Sethi et al. Inpatient Burden of Constipation in the United States: An Analysis of National Trends from 1997-2010: Presidential Poster: 1882
Gravesen The value of sanocrysin in relation to the different phases of pulmonary tuberculosis
Ohara et al. Analysis of risk factors for lenalidomide-associated skin rash and desensitization protocol using prednisolone administration in patients with multiple myeloma